Composition comprising CHP (cyclo-his pro) for preventing, improving or treating of bone loss related disease
Inventors
Jung, Hoe Yune • LEE, Heon Jong • LEE, Do Hyun
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11975041-B2
Publication Date
2024-05-07
Expiration Date
Abstract
A composition containing cyclo-hispro (CHP) and its use in preventing, alleviating, or treating bone loss diseases are disclosed. The composition contains CHP or a CHP-containing prostate extract.
Core Innovation
The invention relates to preventing, alleviating, or treating bone loss diseases by administering a composition containing cyclo-hispro (CHP) or a CHP-containing prostate extract. The disclosed approach emphasizes a biological rationale tied to decreased osteogenic differentiation and identifies osteoporosis among the bone loss diseases addressed.
The core compositions include cyclo-hispro or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier, and embodiments further include a prostate extract comprising cyclo-hispro. The document also describes an embodiment where the composition does not contain zinc, and some embodiments specify a prostate extract in which fat is removed.
The disclosed effects are supported by osteogenic differentiation and bone measurement findings. The document states that CHP promotes osteogenic differentiation and increases bone mineral density, including micro-CT observations that show increased femur bone mineral density and bone volume fraction versus an ovariectomized control.
Claims Coverage
The partial claim set includes four independent claims. Across the independent claims, the inventive features are centered on using cyclo-hispro or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier to treat bone loss diseases caused by decreased osteogenic differentiation, with additional independent-claim coverage for enhancing bone mineral density and for promoting osteogenic differentiation, and one independent claim that specifies a composition not containing zinc while using cyclo-hispro directly.
Treating a bone loss disease by administering cyclo-hispro without zinc
A method for treating a bone loss disease in a subject in need thereof by administering an effective amount of a composition consisting of cyclo-hispro or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, wherein the composition does not contain zinc, and wherein the bone loss disease is caused by decreased osteogenic differentiation.
Treating a bone loss disease with a prostate extract comprising cyclo-hispro
A method for treating a bone loss disease in a subject in need thereof by administering an effective amount of a composition consisting of a prostate extract comprising cyclo-hispro or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, wherein the bone loss disease is caused by decreased osteogenic differentiation.
Enhancing bone mineral density using cyclo-hispro with a carrier
A method for enhancing bone mineral density in a subject in need thereof by administering an effective amount of a composition comprising cyclo-hispro or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Promoting osteogenic differentiation using cyclo-hispro with a carrier
A method for promoting osteogenic differentiation in a subject in need thereof by administering an effective amount of a composition comprising cyclo-hispro or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Overall, the claim coverage focuses on therapeutic methods using cyclo-hispro or pharmaceutically acceptable salts with a pharmaceutically acceptable carrier, specifically for bone loss diseases caused by decreased osteogenic differentiation, and additionally for enhancing bone mineral density and promoting osteogenic differentiation, with one independent claim requiring that the composition does not contain zinc.
Stated Advantages
Promotes osteogenic differentiation.
Increases bone mineral density.
Documented Applications
Preventing, alleviating, or treating bone loss diseases, with emphasis on osteoporosis.
Using compositions as health functional foods and quasi-drug compositions is described.
Oral care products and alveolar bone disease are mentioned in the disclosed contexts.
Interested in licensing this patent?